Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation

European Heart Journal

Volumn 20, Issue 3, 1999, Pages 211-220

  Yamada, T ^a   Fukunami, M ^a   Shimonagata, T ^a   Kumagai, K ^a   Sanada, S ^a   Ogita, H ^a   Asano, Y ^a   Hori, M ^b   Hoki, N ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Body surface mapping; P wave signal averaged ECG

Indexed keywords

PILSICAINIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; P WAVE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BODY SURFACE POTENTIAL MAPPING; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; ROC CURVE; TACHYCARDIA, PAROXYSMAL;

EID: 0033057611     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1281     Document Type: Article

References (21)

1. Engel TR, Lunch JC, Leddy CL, Gonzales ADC. Diagnostic implication of atrial vulnerability. PACE. 2:1979;208-214.
2. Hashiba K, Tanigawa M, Fukatani M. Electrophysiologic properties of atrial muscle in paroxysmal atrial fibrillation. Am J Cardiol. 64:1989;20J-3J.
3. Cosio FG, Palacios J, Vidal JM, Cocina EG, Gomez-Sanchez MA, Tamargo L. Electrophysiologic studies in atrial fibrillation. Slow conduction of premature impulses: a possible manifestation of the background for reentry. Am J Cardiol. 51:1983;122-130.
4. Simpson RJ, Foster JR, Gettes LS. Atrial excitability and conduction defect. Am J Cardiol. 50:1982;1331-1337.
5. Ohe T, Matsuhisa M, Kamakura S, Yamada J, Sato I, Nakajima K. Relation between the widening of the fragmented atrial activity zone and atrial fibrillation. Am J Cardiol. 53:1983;1219-1222.
6. Tanigawa M, Fukatani M, Konoe A, Isomoto S, Kadena M, Hashiba K. Prolonged and fractionated right atrial electrograms during sinus rhythm in patients with paroxysmal atrial fibrillation and sick sinus syndrome. J Am Coll Cardiol. 17:1991;403-408.
7. Fukunami M, Yamada T, Ohmori M. Detection of patients at risk for paroxysmal atrial fibrillation during sinus rhythm by P wave-triggered signal-averaged electrocardiogram. Circulation. 83:1991;162-169.
8. Yamada T, Fukunami M, Ohmori M. Characteristics of frequency content of atrial signal-averaged electrocardiograms during sinus rhythm in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 19:1992;559-563.
9. Stafford PJ, Turner I, Vincent R. Quantitative analysis of signal-averaged P waves in idiopathic paroxysmal atrial fibrillation. Am J Cardiol. 68:1991;751-755.
10. Guidera SA, Steinberg JS. The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation. J Am Coll Cardiol. 21:1993;1645-1651.
11. Hattori Y, Inomata N, Aisaka K, Ishihara T. Electrophysiological actions of N-(2,6-dimethylphenyl)-8-pyrrolizine-acetamide hydrochloride hemihydrate (SUN1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol. 8:1986;998-1002.
12. Hattori Y, Hidaka T, Aisaka K, Satoh F, Ishihara T. Effect of SUN1165, a new potent antiarrhythmic agent, on the kinetics of the rate-dependent of Na channels and ventricular conduction of extrasystoles. J Cardiovasc Pharmacol. 11:1988;407-412.
13. Terazawa T, Suzuki M, Goto T. Suppressive effect of SUN1165 on supraventricular tachycardia. Am Heart J. 121:1991;1437-1444.
14. Atarashi H, Ino T, Hayakawa H. Electrophysiologic testings and effects of antiarrhythmic drugs in patients with paroxysmal supraventricular tachycardia. Jpn Circ J. 56 (Suppl 5):1992;1451-1453.
15. Atarashi H, Inoue H, Hiejima K, Hayakawa H. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation). Am J Cardiol. 78:1996;694-697.
16. Simson MB. Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation. 64:1981;235-242.
17. Breithardt G, Schwarzmaier J, Borgreffe M, Haerten K, Seipel L. Prognostic significance of late potentials after acute myocardial infarction. Eur Heart J. 4:1983;487-495.
18. Gomes JA, Winters SL, Stewart D, Horowitz S, Miner M, Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year myocardial infarction: Based on signal-averaged electro-cardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol. 10:1987;349-357.
19. Cain ME, Ambos HD, Markham J, Lindsay BD, Arthur RM. Diagnostic implications of spectral and temporal analysis of the entire cardiac cycle in patients with ventricular tachycardia. Circulation. 83:1991;1637-1648.
20. Steinberg JS, Zelenkofske S, Wong SC, Gelernt M, Scicca R, Menchavez E. Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. Circulation. 88:1993;2618-2622.
21. Abe Y, Fukunami M, Yamada T. Prediction of transition to chronic atrial fibrillation in patients with paroxysmal atrial fibrillation by signal-averaged electrocardiography: a prospective study. Circulation. 96:1997;2612-2616.